Choose HA†
OAKneePainRelief.com

References

  1. Tang T, Muneta T, Ju YJ, et al. Serum keratin sulfate transiently increases in the early stage of osteoarthritis during strenuous running of rats; protective effect of intraarticular hyaluronan injection. Arthritis Res Ther. 2008;10(1):R13. doi: 10.1186/ar2363
  2. Takahashi K, Hashimoto S, Kubo T, Hirasawa Y, Lotz M, Amiel D. Effect of hyaluronan on chondrocyte apoptosis and nitric oxide production in experimentally induced osteoarthritis. J Rheumatol. 2000;27(7):1713-20.
  3. Fukuda K, Dan H, Takayama M, Kumano F, Saitoh M, Tanaka S. Hyaluronic acid increases proteoglycan synthesis in bovine articular cartilage in the presence of interleukin-1. J Pharm Exp Ther. 1996;277(3):1672-5.
  4. Asari A, Miyauchi S, Matsuzaka S, Ito T, Kominami E, Uchiyama Y. Molecular weight-dependent effects of hyaluronate on the arthritic synovium. Arch Histol Cytol. 1998;61(2):125-35.
  5. Mitsui Y, Gotoh M, Nakama K, Yamada T, Higuchi F, Nagata K. Hyaluronic acid inhibits mRNA expression of proinflammatory cytokines and cyclooxygenase-2/prostaglandin E2 production via CD44 in interleukin-1-stimulated subacromial synovial fibroblasts from patients with rotator cuff disease. J Orthop Res. 2008;26(7):1032-7. doi: 10.1002/jor.20558
  6. Wang CT, Lin YT, Chiang BL, Lin YH, Hou SM. High molecular weight hyaluronic acid down-regulates the gene expression of osteoarthritis-associated cytokines and enzymes in fibroblast-like synoviocytes from patients with early osteoarthritis. Osteoarthritis Cartilage. 2006;14(12):1237-47. doi: 10.1016/j.joca.2006.05.009
  7. Julovi SM, Yasuda T, Shimizu M, Hiramitsu T, Nakamura T. Inhibition of interleukin-1ß-stimulated production of matrix metalloproteinases by hyaluronan via CD44 in human articular cartilage. Arthritis Rheum. 2004;50(2):516-25.
  8. Waddell DD, Kolomytkin OV, Dunn S, Marino AA. Hyaluronan suppresses IL-1ß-induced metalloproteinase activity from synovial tissue. Clin Orthop Relat Res. 2007;465:241-8. doi: 10.1097/BLO.0b013e31815873f9
  9. McGrath AF, McGrath AM, Jessop ZM, et al. A comparison of intra-articular hyaluronic acid competitors in the treatment of mild to moderate knee osteoarthritis. J Arthritis. 2013;2(1):108. doi: 10.4172/2167-7921.1000108
  10. Leighton R, Åkermark C, Therrien R, et al. NASHA hyaluronic acid vs. methylprednisolone for knee osteoarthritis: a prospective, multi-centre, randomized, non-inferiority trial. Osteoarthritis Cartilage. 2014;22(1):17-25. doi: 10.1016/j.joca.2013.10.009
  11. Altman R, Lim S, Steen RG, Dasa V. Hyaluronic acid injections are associated with delay of total knee replacement surgery in patients with knee osteoarthritis: evidence from a large U.S. health claims database. PLoS One. 2015;10(12):e0145776. doi: 10.1371/journal.pone.0145776
  12. American Academy of Orthopaedic Surgeons. Arthritis of the knee. Last updated June 2014. https://orthoinfo.aaos.org/en/diseases–conditions/arthritis-of-the-knee
  13. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Osteoarthritis. Last updated May 30, 2016. www.niams.nih.gov/health-topics/osteoarthritis
  14. Zhang H, Zhang K, Zhang X, et al. Comparison of two hyaluronic acid formulations for safety and efficacy (CHASE) study in knee osteoarthritis: a multicenter, randomized, double-blind, 26-week non-inferiority trial comparing Durolane to Artz. Arthritis Res Ther. 2015;17:51. doi: 10.1186/s13075-015-0557-x
  15. Barbour KE, Helmick CG, Boring M, Brady TJ. Vital signs: prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation—United States, 2013–2015. Morb Mortal Wkly Rep. 2017;66(9):246-53. doi: 10.15585/mmwr.mm6609e1
  16. Arthritis Foundation. What is osteoarthritis? Accessed February 9, 2019. www.arthritis.org/about-arthritis/types/osteoarthritis/what-is-osteoarthritis.php
  17. DUROLANE [package insert]. Durham, NC: Bioventus LLC; 2017.
  18. Arthritis Foundation. Osteoarthritis causes. Accessed February 9, 2019. www.arthritis.org/about-arthritis/types/osteoarthritis/causes.php
  19. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum. 2000;43(9):1905-15. doi: 10.1002/1529-0131(200009)43:9<1905::AID-ANR1>3.0.CO;2-P
  20. Arthritis Foundation. Osteoarthritis treatment. Accessed February 9, 2019. www.arthritis.org/about-arthritis/types/osteoarthritis/treatment.php
  21. Messier SP, Resnik AE, Beavers DP, et al. Intentional weight loss in overweight and obese patients with knee osteoarthritis: is more better? Arthritis Care Res (Hoboken). 2018;70(11):1569-75. doi: 10.1002/acr.23608
  22. Arthritis Foundation. Hyaluronic acid injections for osteoarthritis. Accessed May 8, 2016. www.arthritis.org/living-with-arthritis/treatments/medication/drug-types/other/hyaluronic-acid-injections.php
  23. McAlindon TE, LaValley MP, Harvey WF, et al. Effect of intra-articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis: a randomized clinical trial. JAMA. 2017;317(19):1967-75. doi:10.1001/jama.2017.5283
  24. Altman RD, Manjoo A, Fierlinger A, Niazi F, Nicholls M. The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review. BMC Musculoskelet Disord. 2015;16:321. doi: 10.1186/s12891-015-0775-z
  25. Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. 2015;162(1):46-54. doi: 10.7326/M14-1231
  26. Krocker D, Matziolis G, Tuischer J, et al. Reduction of arthrosis associated knee pain through a single intra-articular injection of synthetic hyaluronic acid. Z Rheumatol. 2006;65(4):327-31. doi: 10.1007/s00393-006-0063-2
  27. Ågerup B, Berg P, Åkermark C. Non-animal stabilized hyaluronic acid: a new formulation for the treatment of osteoarthritis. BioDrugs. 2005;19(1):23-30. doi: 10.2165/00063030-200519010-00003
  28. Balazs EA, Denlinger JL. Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol Suppl. 1993;39:3-9.
  29. Edsman K, Hjelm R, Lärkner H, et al. Intra-articular duration of Durolane™ after single injection into the rabbit knee. Cartilage. 2011;2(4)384-8. doi: 10.1177/1947603511400184
  30. Lindqvist U, Tolmachev V, Kairemo K, Aström G, Jonsson E, Lundqvist H. Elimination of stabilised hyaluronan from the knee joint in healthy men. Clin Pharmacokinet. 2002;41(8):603-13. doi: 10.2165/00003088-200241080-00004
  31. Larsen NE, Dursema HD, Pollak CT, Skrabut EM. Clearance kinetics of a hylan-based viscosupplement after intra-articular and intravenous administration in animal models. J Biomed Mater Res B Appl Biomater. 2012;100(2):457-62. doi: 10.1002/jbm.b.31971
  32. Sakamoto T, Mizuno S, Miyazaki K, et al. Biological fate of sodium hyaluronate (SPH). (1) Studies on distribution, metabolism and excretion of 14C-SPH in rabbits after intraarticular administration. Pharmacometrics. 1984;28(2):375-87.
  33. GELSYN-3 [package insert]. Durham, NC: Bioventus LLC; 2015.
  34. IBSA Institut Biochimique SA. Technologies. Accessed June 2016. www.ibsagroup.com/innovation/technologies.html
  35. Pavelka K, Uebelhart D. Efficacy evaluation of highly purified intra-articular hyaluronic acid (Sinovial®) vs. hylan G-F20 (Synvisc®) in the treatment of symptomatic knee osteoarthritis. A double-blind, controlled, randomized, parallel-group non-inferiority study. Osteoarthritis Cartilage. 2011;19(11):1294-300. doi: 10.1016/j.joca.2011.07.016
  36. Parmet S, Lynm C, Glass RM. Osteoarthritis of the knee. JAMA. 2003;289(8):1068. doi:10.1001/jama.289.8.1068
  37. HTL Biotechnology. Safety by design. Accessed June 2016. www.htl-bio.com/products/304/safety_by_design.php
  38. Bioventus LLC. Sinovial sales data, RPT-000529. Data on file.
  39. Bioventus LLC. Based on Seikagaku Corporation Annual Report 2013. Regulatory file 12000.29. Data on file, RPT-000309.
  40. Strand V, Conaghan PG, Lohmander LS, et al. An integrated analysis of five double-blind, randomized controlled trials evaluating the safety and efficacy of a hyaluronan product for intra-articular injection in osteoarthritis of the knee. Osteoarthritis Cartilage. 2006;14(9):859-66. doi: 1016/j.joca.2006.02.012
  41. Sun SF, Hsu CW, Hwang CW, et al. Hyaluronate improves pain, physical function and balance in the geriatric osteoarthritic knee: a 6-month follow-up study using clinical tests. Osteoarthritis Cartilage. 2006;14(7):696-701. doi.org/10.1016/j.joca.2006.01.010
  42. SUPARTZ FX [package insert]. Durham, NC: Bioventus LLC; 2015.
  43. Day R, Brooks P, Conaghan PG, Petersen M, Multicenter Trial Group. A double blind, randomized, multicenter, parallel group study of the effectiveness and tolerance of intraarticular hyaluronan in osteoarthritis of the knee. J Rheumatol. 2004;31(4):775-82.
  44. Bioventus LLC. SUPARTZ FX file of prospective clinical studies. Regulatory file 29000.142. Data on file, RPT-000310.
  45. Tang T, Muneta T, Ju YJ, et al. Serum keratin sulfate transiently increases in the early stage of osteoarthritis during strenuous running of rats: protective effect of intraarticular hyaluronan injection. Arthritis Res Ther. 2008;10:R13. doi: 10.1186/ar2363
  46. Ohshima Y, Yokota S, Kasama K, Ono H. Comparative studies on levels of proteins, bacterial endotoxins and nucleic acids in hyaluronan preparations used to treat ostheoarthritis of the knee. Could residual proteins and bacterial endotoxins relate to complications? Jpn Pharmacol Ther. 2004;32(10):655-62.